United States' Food and Drug Administration has granted approval to Ranbaxy Laboratories Ltd to manufacture and market 40 mg capsules of Fluoxetine, a drug used in treatment of obsessive-compulsive disorders.\n\n
The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.
Kapiva's plans to introduce allopathy-like doses of ayurvedic remedies for the millennial consumer finds traction.
Riluzole is indicated for the treatment of amyotrophic lateral sclerosis.
Dinesh Thakur is famous for exposing Ranbaxy safety problems
Facing arbitration claims by Daiichi Sankyo, Ranbaxy's former Indian promoters - Malvinder Mohan Singh, his brother Shivinder Mohan Singh and family - are counting on certain clauses in the share purchase agreement (SPA) signed with the Japanese company on June 11, 2008, to claim immunity from damages.
Goa on Sunday joined several other states in banning the sale of Nestle's instant noodle brand 'Maggi' which is at the centre of a raging nationwide row over food safety concerns.
The worms were detected in Elferri capsules, manufactured by a Goan company. The FDA has initiated a probe.
Financials were the top losers while oil shares also declined amid weak crude oil prices.
In the Sensex pack, ICICI Bank emerged as the top gainer by rising 0.97 per cent, while Tata Steel advanced 0.92 per cent.
Global generic drugs producer Sandoz has opened its third plant in India at Navi Mumbai with annual production capacity of one billion tablets and capsules.
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments
The 50-share NSE Nifty stayed in the positive zone and retook the 9,900-mark to hit a high of 9,905.05 as buying paced up towards the fag end. It settled higher by 72.45 points, or 0.74 per cent, at 9,899.60.
The presence of ants was detected at Alibag in Maharashtra and subsequently a complaint was lodged with the Food and Drug Administration authorities.
Lupin was the top gainer after the USFDA cleared its Goa facility
The procedure, however, would cost around Rs 75,000-100,000 more than conventional angioplasty.
Ranbaxy Laboratories on Friday said it has received tentative approval from US Food and Drug Administration to manufacture and market Ofloxacin, the generic version of Ortho Mcneil Pharmaceutical Inc's Floxin.
Experts question Nestle's silence over Maggi controversy.
We are surrounded by food that is contaminated, adulterated and does not meet Indian safety and packaging standards, says Abheet Singh Sethi/IndiaSpend.com.
Punishing brand ambassadors shows that the government is only interested in going after the low hanging fruit, says Tanmaya Nanda.
Daiichi alleged that Singh brothers had concealed and misrepresented critical information concerning US Food and Drug Administration and Department of Justice investigations into Ranbaxy
The broader markets ended negatively with mid-caps and small-caps shedding 0.5 per cent on the BSE.
The introduction of e-pharmacy, to protect the interest of a handful of players, would hamper the interest of 800,000 chemists and 80 lakh workers and their families
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Its Waluj manufacturing facility in Maharashtra failed to meet the good manufacturing norms prescribed by the UK drug regulator.
A widening probe by US authorities involving top drug companies following complaints of price fixing of generics was a point of worry for the participants, said analysts.
Apple on Wednesday launched the Series 4 of the Watch and three phones -- iPhone XS, XS Max and XR -- at the Steve Jobs Theater in Cupertino, California.
Indian drug maker Alembic Ltd plans to expand its bulk drugs business in the United States by joining hands with US formulations makers, the Bombay Stock Exchange said on Thursday.
The company did not comply to the 'good manufacturing practice' norms.
The names of two Indian-Americans -- Seema Verma and Bobby Jindal -- have emerged as possible candidates.
Lupin will fund the buy through $100 mn cash reserves and a bridge loan.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances